CORRECTING and REPLACING Sucampo Standardizes on Veeva Vault for a Single Source of Truth and Enterprise-wide Capability

PLEASANTON, Calif.–(BUSINESS WIRE)–Headline of release should read: Sucampo Standardizes on Veeva Vault for
a Single Source of Truth and Enterprise-wide Capability (instead of
Sucampo Standardizes on Veeva Vault for a Single Source of Truth
Enterprise-wide)
The corrected release reads:

SUCAMPO STANDARDIZES ON VEEVA VAULT FOR A SINGLE SOURCE OF TRUTH AND
ENTERPRISE-WIDE CAPABILITY

High-growth biopharmaceutical company sets content and information
management foundation for greater speed, agility, and compliance
throughout the product lifecycle

Veeva Systems (NYSE:VEEV) announced today that Sucampo Pharmaceuticals
(NASDAQ:SCMP), a fast-growing global biopharmaceutical company, has
standardized on the Veeva
Vault platform and suite of applications to provide a unified
foundation for content and information management. Veeva’s solution will
help Sucampo eliminate information and process siloes across functional
teams, regions, and partners, enabling Sucampo to make information fully
accessible and actionable. Veeva Vault allows Sucampo to increase
efficiency and strengthen compliance with a single source of truth for
content plus life sciences-specific solutions that streamline key
processes throughout the product lifecycle.
Sucampo’s move to Veeva Vault is the cornerstone of its initiative to
ensure greater efficiency and leverage valuable information created at
every stage of a product – including clinical, quality, regulatory, and
commercial. “There is a wealth of insight that can be gleaned when you
have end-to-end visibility spanning the value chain,” explained Michael
Gammons, Sucampo’s chief information officer and vice president of
information technology. “As a rapidly growing company, it’s critical we
set a foundation for future growth by deploying industry-specific
applications that support our most crucial business functions, all on
one common platform. Veeva Vault is the foundation and provides the
process optimization and single source of truth we need for agility and
speed across the product lifecycle.”
Having valuable product information quickly accessible for future use in
all functional areas, plus key process metrics, can have tremendous
impact on the business. For instance, early-stage analysis of a compound
can be critical to compiling submissions documents for licensing
applications years later. With Veeva Vault, all content and audit trails
are in a central system of record, reducing complexity and cost.
Veeva Vault also aligns with Sucampo’s corporate initiative to leverage
the efficiencies and agility of Veeva’s industry cloud. “Our IT
department is focused on solving business problems, and, with Veeva
Vault, we get a world-class technology foundation plus tailored content
and information management solutions that fit our business. We don’t
have infrastructure to manage or software we need to customize,” said
Gammons. “As important, Veeva provides frequent enhancements so we’re
always working with the latest innovations instead of waiting years and
investing more to implement an incremental version upgrade.”
Over the coming months, Sucampo will drive an aggressive implementation
plan to rollout key Veeva Vault solutions worldwide including: Vault
eTMF for clinical trial master file management; Vault
QualityDocs for managing quality, manufacturing, and validation
documents; and Vault
Submissions, part of the Vault RIM suite, for regulatory submissions.
In related news today, Veeva introduced new innovative features in its
latest release of Veeva Vault, version 14, to empower life sciences
companies to streamline their business processes across an increasingly
complex ecosystem of internal and external stakeholders. Read
today’s press release about how the newest release of Veeva Vault is
helping to get products to market faster and more efficiently.
Additional Information
For more on Veeva Vault, visit: veeva.com/vault
Stay
updated on the latest Veeva news on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 400 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit www.veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-K for the period ended January 31, 2016. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov. Further
information on potential risks that could affect actual results will be
included in other filings Veeva makes with the SEC from time to time.